Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early Breast Cancer: The OPTIMA Prelim Trial-Reference-Cited by-同舟云学术

Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early Breast Cancer: The OPTIMA Prelim Trial

Published:2017-12 Issue:10 Volume:20 Page:1311-1318
ISSN:1098-3015
Container-title:Value in Health
language:en
Short-container-title:Value in Health

Author:

Hall Peter S.,Smith Alison,Hulme Claire,Vargas-Palacios Armando,Makris Andreas,Hughes-Davies Luke,Dunn Janet A.,Bartlett John M.S.,Cameron David A.,Marshall Andrea,Campbell Amy,Macpherson Iain R.,Dan Rea ,Francis Adele,Earl Helena,Morgan Adrienne,Stein Robert C.,McCabe Christopher

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health,Health Policy

Reference26 articles.

1. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Senkus;Ann Oncol,2013

2. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA);Biganzoli;Lancet Oncol,2012

3. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials;Lancet,2005

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A scoping review of evaluation and acceptability criteria for the accuracy of cost estimates in health economic evaluations;2024 IEEE 28th International Conference on Intelligent Engineering Systems (INES);2024-07-17

2. Enhancing clinical decision support with genomic tools in breast cancer: A Scottish perspective;The Breast;2024-06

3. Consolidated Health Economic Evaluation Reporting Standards - Value of Information (CHEERS-VOI): Explanation and Elaboration;Value in Health;2023-10

4. Cost-utility analysis of genomic profiling in early breast cancer in Colombia;Cost Effectiveness and Resource Allocation;2023-07-10

5. Compliance to genomic test recommendations to guide adjuvant chemotherapy decision‐making in the case of hormone receptor‐positive, human epidermal growth factor receptor 2‐negative breast cancer, in real‐life settings;Cancer Medicine;2023-07-06